Graeme Bell
Vorstandsvorsitzender bei Valo Health, Inc.
Aktive Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| Douglas Giordano | M | 61 | 8 Jahre | |
| Judy Lewent | F | 75 |
Valo Health LLC
 Valo Health LLC Packaged SoftwareTechnology Services Valo Health LLC operates as a drug discovery technology company. It offers cloud computing as well as longitudinal and human data to create an entirely new drug discovery and development process. The company was founded in 2019 and is headquartered in Boston, MA.
Valo Health, Inc.
 Valo Health, Inc. Financial ConglomeratesFinance Part of Valo Health LLC, Valo Health, Inc. operates as a development stage company. The company is based in Boston, MA. The company was founded by David A. Berry. David A. Berry has been the CEO since incorporation. | 31 Jahre |
| José Eduardo Vidal | M | - |
Cytoimmune Therapeutics, Inc.
 Cytoimmune Therapeutics, Inc. BiotechnologyHealth Technology Cytoimmune Therapeutics, Inc. is a clinical-stage biotechnology company founded in 2017 and based in Toa, Japan. The American company is focused on developing a pipeline of NK cell therapies for various types of cancer, including lung cancer, acute myeloid leukemia, solid tumors, and multiple myeloma. The private company's lead product, Cyto-102, is a track-NK cell therapy that aims to enter clinical trials in combination with atezolizumab for non-small cell lung cancer in 2022. Cytoimmune Therapeutics also offers cell therapy development and clinical manufacturing services to biotechnology companies and academia. The company's state-of-the-art clinical cell manufacturing facility is custom-built to support the development and commercialization of cutting-edge T cell or NK cell therapies. The company was founded in 2017 by Michael A. Caligiuri, William Michael Rosellini, and Jianhua Yu, Ph.D. José Eduardo Vidal has been the CEO of the company since 2021. | 3 Jahre |
| Frank Verwiel | M | 61 | 7 Jahre | |
| Margaret M. Madden | F | - | 8 Jahre | |
| William Michael Rosellini | M | 44 |
Cytoimmune Therapeutics, Inc.
Cytoimmune Therapeutics, Inc. BiotechnologyHealth Technology Cytoimmune Therapeutics, Inc. is a clinical-stage biotechnology company founded in 2017 and based in Toa, Japan. The American company is focused on developing a pipeline of NK cell therapies for various types of cancer, including lung cancer, acute myeloid leukemia, solid tumors, and multiple myeloma. The private company's lead product, Cyto-102, is a track-NK cell therapy that aims to enter clinical trials in combination with atezolizumab for non-small cell lung cancer in 2022. Cytoimmune Therapeutics also offers cell therapy development and clinical manufacturing services to biotechnology companies and academia. The company's state-of-the-art clinical cell manufacturing facility is custom-built to support the development and commercialization of cutting-edge T cell or NK cell therapies. The company was founded in 2017 by Michael A. Caligiuri, William Michael Rosellini, and Jianhua Yu, Ph.D. José Eduardo Vidal has been the CEO of the company since 2021. | 5 Jahre |
| Tom Glocer | M | 63 | 17 Jahre | |
| P. Smalley | M | - |
Valo Health, Inc.
Valo Health, Inc. Financial ConglomeratesFinance Part of Valo Health LLC, Valo Health, Inc. operates as a development stage company. The company is based in Boston, MA. The company was founded by David A. Berry. David A. Berry has been the CEO since incorporation.
Valo Health LLC
Valo Health LLC Packaged SoftwareTechnology Services Valo Health LLC operates as a drug discovery technology company. It offers cloud computing as well as longitudinal and human data to create an entirely new drug discovery and development process. The company was founded in 2019 and is headquartered in Boston, MA. | 3 Jahre |
| Harsha Ramalingam | M | 65 |
Valo Health, Inc.
Valo Health, Inc. Financial ConglomeratesFinance Part of Valo Health LLC, Valo Health, Inc. operates as a development stage company. The company is based in Boston, MA. The company was founded by David A. Berry. David A. Berry has been the CEO since incorporation.
Valo Health LLC
Valo Health LLC Packaged SoftwareTechnology Services Valo Health LLC operates as a drug discovery technology company. It offers cloud computing as well as longitudinal and human data to create an entirely new drug discovery and development process. The company was founded in 2019 and is headquartered in Boston, MA. | - |
| Michael A. Caligiuri | M | 68 |
Cytoimmune Therapeutics, Inc.
Cytoimmune Therapeutics, Inc. BiotechnologyHealth Technology Cytoimmune Therapeutics, Inc. is a clinical-stage biotechnology company founded in 2017 and based in Toa, Japan. The American company is focused on developing a pipeline of NK cell therapies for various types of cancer, including lung cancer, acute myeloid leukemia, solid tumors, and multiple myeloma. The private company's lead product, Cyto-102, is a track-NK cell therapy that aims to enter clinical trials in combination with atezolizumab for non-small cell lung cancer in 2022. Cytoimmune Therapeutics also offers cell therapy development and clinical manufacturing services to biotechnology companies and academia. The company's state-of-the-art clinical cell manufacturing facility is custom-built to support the development and commercialization of cutting-edge T cell or NK cell therapies. The company was founded in 2017 by Michael A. Caligiuri, William Michael Rosellini, and Jianhua Yu, Ph.D. José Eduardo Vidal has been the CEO of the company since 2021. | 5 Jahre |
| Hilary Malone | M | 59 |
Valo Health, Inc.
Valo Health, Inc. Financial ConglomeratesFinance Part of Valo Health LLC, Valo Health, Inc. operates as a development stage company. The company is based in Boston, MA. The company was founded by David A. Berry. David A. Berry has been the CEO since incorporation.
Valo Health LLC
Valo Health LLC Packaged SoftwareTechnology Services Valo Health LLC operates as a drug discovery technology company. It offers cloud computing as well as longitudinal and human data to create an entirely new drug discovery and development process. The company was founded in 2019 and is headquartered in Boston, MA. | 4 Jahre |
| Paul Biondi | M | 54 |
Valo Health LLC
Valo Health LLC Packaged SoftwareTechnology Services Valo Health LLC operates as a drug discovery technology company. It offers cloud computing as well as longitudinal and human data to create an entirely new drug discovery and development process. The company was founded in 2019 and is headquartered in Boston, MA.
Valo Health, Inc.
Valo Health, Inc. Financial ConglomeratesFinance Part of Valo Health LLC, Valo Health, Inc. operates as a development stage company. The company is based in Boston, MA. The company was founded by David A. Berry. David A. Berry has been the CEO since incorporation. | - |
| David Epstein | M | 62 |
Valo Health, Inc.
Valo Health, Inc. Financial ConglomeratesFinance Part of Valo Health LLC, Valo Health, Inc. operates as a development stage company. The company is based in Boston, MA. The company was founded by David A. Berry. David A. Berry has been the CEO since incorporation.
Valo Health LLC
Valo Health LLC Packaged SoftwareTechnology Services Valo Health LLC operates as a drug discovery technology company. It offers cloud computing as well as longitudinal and human data to create an entirely new drug discovery and development process. The company was founded in 2019 and is headquartered in Boston, MA. | 5 Jahre |
| Richard T. Santulli | M | - |
Cytoimmune Therapeutics, Inc.
Cytoimmune Therapeutics, Inc. BiotechnologyHealth Technology Cytoimmune Therapeutics, Inc. is a clinical-stage biotechnology company founded in 2017 and based in Toa, Japan. The American company is focused on developing a pipeline of NK cell therapies for various types of cancer, including lung cancer, acute myeloid leukemia, solid tumors, and multiple myeloma. The private company's lead product, Cyto-102, is a track-NK cell therapy that aims to enter clinical trials in combination with atezolizumab for non-small cell lung cancer in 2022. Cytoimmune Therapeutics also offers cell therapy development and clinical manufacturing services to biotechnology companies and academia. The company's state-of-the-art clinical cell manufacturing facility is custom-built to support the development and commercialization of cutting-edge T cell or NK cell therapies. The company was founded in 2017 by Michael A. Caligiuri, William Michael Rosellini, and Jianhua Yu, Ph.D. José Eduardo Vidal has been the CEO of the company since 2021. | - |
| Dalton Smart | M | 58 | 15 Jahre | |
| Jorge Conde | M | 47 |
Tmunity Therapeutics, Inc.
 Tmunity Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Tmunity Therapeutics, Inc. develops novel products that free the immunological potential of T cells to treat disease indications. It develops novel T Cell Receptor (TCR) engineered T cells, regulatory T cells (Treg), and universal engineered T cell platforms. The company was founded by Carl H. June, Anne Chew, Bruce Levine, Yangbing Zhao, James L. Riley and Bruce Blazar and is headquartered in Philadelphia, PA. | 5 Jahre |
| Patrick M. Gray | M | 75 |
Tmunity Therapeutics, Inc.
Tmunity Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Tmunity Therapeutics, Inc. develops novel products that free the immunological potential of T cells to treat disease indications. It develops novel T Cell Receptor (TCR) engineered T cells, regulatory T cells (Treg), and universal engineered T cell platforms. The company was founded by Carl H. June, Anne Chew, Bruce Levine, Yangbing Zhao, James L. Riley and Bruce Blazar and is headquartered in Philadelphia, PA. | 5 Jahre |
| Akiko Miyashita | F | 68 |
Valo Health LLC
Valo Health LLC Packaged SoftwareTechnology Services Valo Health LLC operates as a drug discovery technology company. It offers cloud computing as well as longitudinal and human data to create an entirely new drug discovery and development process. The company was founded in 2019 and is headquartered in Boston, MA. | 5 Jahre |
| Douglas Williams | M | 66 |
Cytoimmune Therapeutics, Inc.
Cytoimmune Therapeutics, Inc. BiotechnologyHealth Technology Cytoimmune Therapeutics, Inc. is a clinical-stage biotechnology company founded in 2017 and based in Toa, Japan. The American company is focused on developing a pipeline of NK cell therapies for various types of cancer, including lung cancer, acute myeloid leukemia, solid tumors, and multiple myeloma. The private company's lead product, Cyto-102, is a track-NK cell therapy that aims to enter clinical trials in combination with atezolizumab for non-small cell lung cancer in 2022. Cytoimmune Therapeutics also offers cell therapy development and clinical manufacturing services to biotechnology companies and academia. The company's state-of-the-art clinical cell manufacturing facility is custom-built to support the development and commercialization of cutting-edge T cell or NK cell therapies. The company was founded in 2017 by Michael A. Caligiuri, William Michael Rosellini, and Jianhua Yu, Ph.D. José Eduardo Vidal has been the CEO of the company since 2021. | 3 Jahre |
| Sanat Chattopadhyay | M | - | 15 Jahre | |
| Pamela Eisele | F | - | 15 Jahre | |
| Shreeram Aradhye | M | 62 |
Valo Health LLC
Valo Health LLC Packaged SoftwareTechnology Services Valo Health LLC operates as a drug discovery technology company. It offers cloud computing as well as longitudinal and human data to create an entirely new drug discovery and development process. The company was founded in 2019 and is headquartered in Boston, MA. | - |
| Denise Williams | F | - | 15 Jahre | |
| Brett Chugg | M | 56 |
Valo Health, Inc.
Valo Health, Inc. Financial ConglomeratesFinance Part of Valo Health LLC, Valo Health, Inc. operates as a development stage company. The company is based in Boston, MA. The company was founded by David A. Berry. David A. Berry has been the CEO since incorporation. | - |
| Bryan Supran | M | - | 8 Jahre |
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Ehemalige Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| David Berry | M | 47 |
Valo Health, Inc.
Valo Health, Inc. Financial ConglomeratesFinance Part of Valo Health LLC, Valo Health, Inc. operates as a development stage company. The company is based in Boston, MA. The company was founded by David A. Berry. David A. Berry has been the CEO since incorporation.
Valo Health LLC
Valo Health LLC Packaged SoftwareTechnology Services Valo Health LLC operates as a drug discovery technology company. It offers cloud computing as well as longitudinal and human data to create an entirely new drug discovery and development process. The company was founded in 2019 and is headquartered in Boston, MA. | 6 Jahre |
| Paul Berns | M | 57 | 4 Jahre | |
| Nessan Bermingham | M | 51 | 3 Jahre | |
| Lucy Shapiro | M | 83 | 16 Jahre | |
| Christina Coughlin | M | 54 |
Cytoimmune Therapeutics, Inc.
Cytoimmune Therapeutics, Inc. BiotechnologyHealth Technology Cytoimmune Therapeutics, Inc. is a clinical-stage biotechnology company founded in 2017 and based in Toa, Japan. The American company is focused on developing a pipeline of NK cell therapies for various types of cancer, including lung cancer, acute myeloid leukemia, solid tumors, and multiple myeloma. The private company's lead product, Cyto-102, is a track-NK cell therapy that aims to enter clinical trials in combination with atezolizumab for non-small cell lung cancer in 2022. Cytoimmune Therapeutics also offers cell therapy development and clinical manufacturing services to biotechnology companies and academia. The company's state-of-the-art clinical cell manufacturing facility is custom-built to support the development and commercialization of cutting-edge T cell or NK cell therapies. The company was founded in 2017 by Michael A. Caligiuri, William Michael Rosellini, and Jianhua Yu, Ph.D. José Eduardo Vidal has been the CEO of the company since 2021.
Tmunity Therapeutics, Inc.
Tmunity Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Tmunity Therapeutics, Inc. develops novel products that free the immunological potential of T cells to treat disease indications. It develops novel T Cell Receptor (TCR) engineered T cells, regulatory T cells (Treg), and universal engineered T cell platforms. The company was founded by Carl H. June, Anne Chew, Bruce Levine, Yangbing Zhao, James L. Riley and Bruce Blazar and is headquartered in Philadelphia, PA. | 4 Jahre |
| Mark Leschly | M | 55 | 14 Jahre | |
| Fred Hassan | M | 78 | 6 Jahre | |
| Craig Thompson | M | 71 | 10 Jahre | |
| Carl Gordon | M | 59 | 2 Jahre | |
| Lucy Day | F | 65 | 14 Jahre | |
| William Rieflin | M | 64 | 5 Jahre | |
| Jean-Marie Canan | M | 68 | 5 Jahre | |
| Keith Leonard | M | 62 | 2 Jahre | |
| Ryan Sullivan | M | 48 | 2 Jahre | |
| Robert Iannone | M | 57 | 6 Jahre | |
| Carlos Eduardo Represas de Almeida | M | 78 | - | |
| Thomas Robert Cech | M | 76 | - | |
| Wendy Yarno | F | 68 | 9 Jahre | |
| Andrew Schiermeier | M | 54 | 3 Jahre | |
| Wendell Wierenga | M | 76 | 2 Jahre | |
| Leslie Brun | M | 72 | 13 Jahre | |
| Caroline Dorsa | F | 64 | 22 Jahre | |
| Richard Henriques | M | 68 | 27 Jahre | |
| Ismail Kola | M | 67 | 4 Jahre | |
| Mojirade James | F | 57 |
Tmunity Therapeutics, Inc.
Tmunity Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Tmunity Therapeutics, Inc. develops novel products that free the immunological potential of T cells to treat disease indications. It develops novel T Cell Receptor (TCR) engineered T cells, regulatory T cells (Treg), and universal engineered T cell platforms. The company was founded by Carl H. June, Anne Chew, Bruce Levine, Yangbing Zhao, James L. Riley and Bruce Blazar and is headquartered in Philadelphia, PA. | 3 Jahre |
| Kenneth Bartizal | M | 72 | 20 Jahre | |
| William N. Kelley | M | 84 | - | |
| David Anstice | M | 75 | 5 Jahre | |
| Anders Hove | M | 58 | 11 Jahre | |
| Harry R. Jacobson | M | 76 | 3 Jahre | |
| Dawn Svoronos | F | 70 | 2 Jahre | |
| Franklin Clyburn | M | 59 | 13 Jahre | |
| Glenn Williams | M | - | 10 Jahre | |
| D. Gilliland | M | 69 | 4 Jahre | |
| Jason Pesile | M | 50 | 2 Jahre | |
| Richard S. Shames | M | - | 4 Jahre | |
| Adele D. Ambrose | F | 67 | - | |
| Mark Shearman | M | 62 | 3 Jahre | |
| Stephen Farrand | M | - | 6 Jahre | |
| Benito Munoz | M | 62 | 9 Jahre | |
| Richard Pasternak | M | 75 | 4 Jahre | |
| Lindsey Trickett | F | - | - | |
| Alexis Ji | M | - | 5 Jahre | |
| Yao Lee | M | 54 | 3 Jahre | |
| Sheldon Koenig | M | 58 | 6 Jahre | |
| Rafael Torgovicky | M | - | 2 Jahre | |
| Lu Amy Sun | M | 67 | 7 Jahre | |
| Maude Tessier | M | 46 | 6 Jahre | |
| Erin McClain | F | - | - | |
| Janelle Anderson | M | 51 | 6 Jahre | |
| Bruno Strigini | M | 63 | 5 Jahre | |
| David Monteith | M | 60 | 5 Jahre | |
| Raul E. Kohan | M | 71 | 1 Jahre | |
| Peter Kim | M | 65 | 5 Jahre | |
| Stefan Oschmann | M | 66 | 20 Jahre | |
| Angelique M. Carbo | F | 59 | 2 Jahre | |
| William G. Bowen | M | 90 | 21 Jahre | |
| Margaret McGlynn | F | 64 | 11 Jahre | |
| Peter Kellogg | M | 67 | 7 Jahre | |
| Peter D. Löscher | M | 66 | 1 Jahre | |
| Dennis Erb | M | - | - | |
| Chandra Vargeese | M | 63 | 1 Jahre | |
| Mervyn Turner | M | 77 | 2 Jahre | |
| Eric Schadt | M | 59 | 8 Jahre | |
| Raymond F. Kerins | M | - | 1 Jahre | |
| François Martelet | M | 64 | 2 Jahre | |
| Christopher Garland | M | - | - | |
| Ray Hill | M | 79 | 18 Jahre | |
| Sandy Matalonis | F | - |
Tmunity Therapeutics, Inc.
Tmunity Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Tmunity Therapeutics, Inc. develops novel products that free the immunological potential of T cells to treat disease indications. It develops novel T Cell Receptor (TCR) engineered T cells, regulatory T cells (Treg), and universal engineered T cell platforms. The company was founded by Carl H. June, Anne Chew, Bruce Levine, Yangbing Zhao, James L. Riley and Bruce Blazar and is headquartered in Philadelphia, PA. | 1 Jahre |
| Mark Stejbach | M | 61 | 21 Jahre | |
| Piotr Bobrowicz | M | - | - | |
| Lawrence D. Senour | M | 59 | - | |
| Silvana Battaglia | F | 56 | 10 Jahre | |
| Aaron Dent | M | - | 6 Jahre | |
| David Parry | M | - | 2 Jahre |
Statistik
| Land | Beziehungen | % des Gesamten |
|---|---|---|
| Vereinigte Staaten | 100 | 100,00% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen
- Börse
- Insiders
- Graeme Bell
- Persönliches Netzwerk